Skin Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Skin Cancer, including details on identification, causes, prevention, treatment. | ||||||||
|
Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders.Gambichler T, Bischoff S, Bechara FG, Altmeyer P, Kreuter A Department of Dermatology, Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany. t.gambichler@klinikum-bochum.de BACKGROUND: Abnormal cell proliferation, which results from deregulation of the cell cycle, is fundamental in tumorigenesis. OBJECTIVES: To investigate the expression of proliferation markers and cell cycle regulators in a range of T cell lymphoproliferative skin diseases. METHODS: We studied skin specimens of 51 patients with parapsoriasis (PP), mycosis fungiodes (MF), or lymphomatoid papulosis (LyP). Immunohistochemistry was performed for Ki-67, proliferating cell nuclear antigen (PCNA), minichromosome maintenance protein 7 (MCM7), and p21. RESULTS: MF with stage IIB-IV and LyP showed a significantly greater number of Ki-67-positive cells than PP (P=0.02 and 0.001) and MF I-IIA (P=0.019 and 0.003), respectively. MCM7 staining revealed significantly higher labeling indices for MF IIB-IV and LyP when compared to PP (P=0.002 and 0.04) and MF I-IIA (P=0.0005 and 0.01), respectively. Compared to PP and MF I-IIA, MF IIB-IV was associated with significantly higher labeling indices for PCNA (P=0.006 and 0.0004). p21 staining was significantly increased in MF IIB-IV and LyP when compared to PP (P=0.006 and 0.003) and MF I-IIA (P=0.003). However, p21 staining was all in all very weak. CONCLUSIONS: Ki-67 and PCNA seem to be useful immunohistological parameters for the correlation with the clinical stage of MF. In the differentiation and prognostication of T cell lymphoproliferative skin disorders, MCM7 may serve as a novel biomarker which is, in contrast to Ki-67 and PCNA, stable throughout the cell cycle. Published 28 December 2007 in J Dermatol Sci, 49(2): 125-32.
© 2004-2008 Skin Cancer Research Today. All Rights Reserved. |
| ||||||
